Contact Information

Currently Enrolling Trials

General Information

A launch has taken place in the U.S. of Amgen's consensus interferon (interferon alfacon-1, INFERGEN) for the treatment of chronic hepatitis C virus infection.

Approval Date: 1997-10-01

Company Name: Amgen

Back to Listings

26Jan
Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup
27Jan
Medical Device Clinical Trials in China: Latest Regulatory Developments
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
26Apr
MAGI's Clinical Research vConference — Spring 2021

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here

INFERGEN (interferon alfacon-1)

Profile

Contact Information

Currently Enrolling Trials

General Information

Upcoming Events

Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

Medical Device Clinical Trials in China: Latest Regulatory Developments

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

MAGI's Clinical Research vConference — Spring 2021

Featured Products

Regenerative Medicine: Steps to Accelerate Development

Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

Simple Changes Can Make Trials More Patient Friendly

Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

Ask the Experts: Trial Operations Adjustments in a Remote World

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.